logo
Share SHARE
FONT-SIZE Plus   Neg

Trius' Antibiotic Tedizolid Shows High Efficacy In Patients With Cellulitis

Trius Therapeutics Inc. (TSRX) reported the results of a subgroup analysis from its first Phase 3 investigational study in Acute Bacterial Skin and Skin Structure Infections or ABSSSI at the European Congress of Clinical Microbiology and Infectious Diseases meeting in London. The data demonstrated that patients with severe cellulitis showed higher clinical response rates following 6 days of treatment with a single 200 milligram daily dose of oral tedizolid phosphate than those treated for 10 days with two 600 milligram daily doses of oral linezolid.

The pivotal Phase 3 study examined the efficacy and safety of tedizolid phosphate versus linezolid in 667 patients with ABSSSI recruited across sites in North America, South America and Europe. Top-line results, reported in December 2011, demonstrated that tedizolid achieved all primary and secondary efficacy outcomes as well as showed significant improvements in key safety and tolerability measurements in the complete study population.

The cellulitis subgroup analysis of the 112 study compared the relative efficacies of tedizolid and linezolid in the European and U.S. patient populations with severe cellulitis with respect to the primary endpoints established by the European or EMA and U.S. regulatory authorities.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
ConAgra Foods Inc. (CAG) reported a net income attributable to the company for the fourth quarter ended May 29, 2016 that declined 43.8 percent from last year. Adjusted earnings per share from continuing operations decreased 5% from the prior year. The comparable earnings per share decline reflected... Another busy month on the FDA calendar has gone by but not without its fair share of hurrahs and heartaches. This is not unexpected, given the uncertainties characterizing drug development and approval processes, which in turn manifest as volatility in stocks belonging to the biotech space. German sporting goods giant Adidas Group (ADDYY.PK, ADDDF.PK) extended its long-term relationship with rapper and fashion designer Kanye West, launching a new line of Yeezy brand products for all genders, the company stated. adidas + Kanye West offers Yeezy branded footwear, apparel and accessories for all genders. Under the deal, West will join with adidas team to lead the development...
comments powered by Disqus
Follow RTT